A Study of VET3-TGI in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT06444815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
Study identification
- NCT ID
- NCT06444815
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 60 participants
Conditions and interventions
Conditions
- Solid Tumor, Adult
- Microsatellite Stable Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma
- Cervical Cancer
- Kidney Cancer
- Renal Cell Carcinoma
- Melanoma Stage IV
- Merkel Cell Carcinoma of Skin
- Mesothelioma
- Non-small Cell Lung Cancer
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Urothelial Carcinoma Bladder
- Squamous Cell Carcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2024
- Primary completion
- Sep 29, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Apr 6, 2026
2024 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| UC Irvine Health | Orange | California | 92868 | Recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| Community Health Network | Indianapolis | Indiana | 46250 | Recruiting |
| UPMC- Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06444815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2026 · Synced Sep 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06444815 live on ClinicalTrials.gov.